Dare Bioscience Inc Total Liabilities
Dare Bioscience Inc total liabilities. Based on the latest financial reports, Dare Bioscience Inc (DARE) has total liabilities worth $29.63 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check DARE asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Dare Bioscience Inc (2011–2025)
Total liabilities of Dare Bioscience Inc from 2011 to 2025. This chart illustrates how Dare Bioscience Inc's total liabilities have evolved over time, based on quarterly financial data.
Dare Bioscience Inc Competitors by Total Liabilities
The table below lists competitors of Dare Bioscience Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Niobay Metals Inc
V:NBY
|
Canada | CA$187.11K |
|
Excite Technology Services Ltd
AU:EXT
|
Australia | AU$17.99 Million |
|
Australian Dairy Nutritionals Ltd
AU:AHF
|
Australia | AU$3.48 Million |
|
BTM Resources Bhd
KLSE:7188
|
Malaysia | RM10.71 Million |
|
European Electric Metals Inc
V:EVX
|
Canada | CA$620.23K |
|
Dataprep Holdings Bhd
KLSE:8338
|
Malaysia | RM12.91 Million |
|
Pilot Energy Ltd
AU:PGY
|
Australia | AU$27.40 Million |
|
Fortune Rise Acquisition Corp
NASDAQ:FRLA
|
USA | $11.37 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Dare Bioscience Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Dare Bioscience Inc assets under control.
Liquidity & Leverage Metrics
Dare Bioscience Inc Total Liabilities Ratios Explained
Dare Bioscience Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 10.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.91 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dare Bioscience Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dare Bioscience Inc (2011–2025)
The table below shows the annual total liabilities of Dare Bioscience Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $29.63 Million | +5.40% |
| 2024-12-31 | $28.11 Million | +6.77% |
| 2023-12-31 | $26.33 Million | -19.52% |
| 2022-12-31 | $32.71 Million | +91.84% |
| 2021-12-31 | $17.05 Million | +95.95% |
| 2020-12-31 | $8.70 Million | +24.29% |
| 2019-12-31 | $7.00 Million | +536.10% |
| 2018-12-31 | $1.10 Million | +13.83% |
| 2017-12-31 | $967.04K | -96.07% |
| 2016-12-31 | $24.58 Million | -16.64% |
| 2015-12-31 | $29.48 Million | +265.42% |
| 2014-12-31 | $8.07 Million | -16.09% |
| 2013-12-31 | $9.62 Million | -90.16% |
| 2012-12-31 | $97.70 Million | +2153.23% |
| 2011-12-31 | $4.34 Million | -- |
About Dare Bioscience Inc
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of… Read more